Namenda XR® (memantine) – First-time generic

- On February 21, 2018, Amneal and Lupin launched AB-rated generic versions of Allergan’s Namenda XR (memantine) 7 mg, 14 mg, 21 mg, 28 mg extended-release capsules.
  - Mylan and Sun received FDA approval of generic Namenda XR on September 28, 2016.
  - Apotex, Anchen, and Zydus received FDA approval of generic Namenda XR on November 22, 2016, June 9, 2017, and August 3, 2017, respectively.
  - These manufacturers may launch generic Namenda XR at any time.

- Namenda XR is approved for the treatment of moderate to severe dementia of the Alzheimer’s type.

- Memantine is also available generically as tablets and oral solution, and as extended-release capsules in combination with donepezil (Namzaric®).
  - The tablets and oral solution carry the same indication as Namenda XR.
  - Namzaric is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.

- According to IQVIA MAT data as of December 2017, Namenda XR had annual sales of approximately $936 million in the U.S.